Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Ark Therapeutics Group plc

1 Apr 2010 11:03

RNS Number : 6222J
Smith & Williamson Investment Mngmt
01 April 2010
 



FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

(Rule 8.3 of the Takeover Code)

 

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

Smith and Williamson Investment Management Limited

Company dealt in

Ark Therapeutics Group plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary

Date of dealing

31st March 2010

 

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

6,604,000 3.16%

(2) Derivatives (other than options)

 

N/A

(3) Options and agreements to purchase/sell

 

N/A

Total

 

6,604,000 3.16%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

 

Long

Short

 

 

Number (%)

Number (%)

(1) Relevant securities

 

N/A

(2) Derivatives (other than options)

 

N/A

(3) Options and agreements to purchase/sell

 

N/A

Total

 

N/A

 

(c) Rights to subscribe (Note 3)

 

Class of relevant security:

 

Details

 

 

 

 

3. DEALINGS (Note 4)

 

(a) Purchases and sales

 

Purchase/sale

 

Number of securities

Price per unit (Note 5)

Sale

Sale

40,000

95,000

10.75p

10.75p

 

 

 

(b) Derivatives transactions (other than options)

 

Product name,

e.g. CFD

Long/short (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

N/A

 

 

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 5)

N/A

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

N/A

 

 

 

(d) Other dealings (including new securities) (Note 4)

 

Nature of transaction (Note 8)

 

Details

Price per unit (if applicable) (Note 5)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

None

 

 

Is a Supplemental Form 8 attached? (Note 9) YES/NO

 

 

Date of disclosure

1st April 2010

Contact name

Stephen Hamilton-Jones

Compliance Manager

Telephone number

020 7131 4734

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

 

 

Notes

 

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETBGGDSDGGBGGB
Date   Source Headline
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
6th Sep 201312:54 pmRNSHolding(s) in Company
4th Sep 20134:40 pmRNSSecond Price Monitoring Extn
4th Sep 20134:35 pmRNSPrice Monitoring Extension
2nd Sep 201312:00 pmRNSHolding(s) in Company
29th Aug 20134:41 pmRNSSecond Price Monitoring Extn
29th Aug 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20139:00 amRNSHalf Yearly Report
16th Aug 20134:40 pmRNSSecond Price Monitoring Extn
16th Aug 20134:35 pmRNSPrice Monitoring Extension
15th Aug 20135:32 pmRNSHolding(s) in Company
14th Aug 20134:56 pmRNSHolding(s) in Company
30th Jul 20134:40 pmRNSSecond Price Monitoring Extn
30th Jul 20134:35 pmRNSPrice Monitoring Extension
23rd Jul 20133:44 pmRNSHolding(s) in Company
9th Jul 20132:00 pmRNSCompany Update
8th Jul 20134:40 pmRNSSecond Price Monitoring Extn
8th Jul 20134:35 pmRNSPrice Monitoring Extension
5th Jul 201310:48 amRNSHolding(s) in Company
5th Jul 20137:00 amRNSCompany Update
27th Jun 20134:40 pmRNSSecond Price Monitoring Extn
27th Jun 20134:35 pmRNSPrice Monitoring Extension
25th Jun 20132:05 pmRNSResults of Annual General Meeting
14th Jun 20134:40 pmRNSSecond Price Monitoring Extn
14th Jun 20134:35 pmRNSPrice Monitoring Extension
4th Jun 20132:48 pmRNSBlocklisting Six Monthly Return
24th May 20134:40 pmRNSSecond Price Monitoring Extn
24th May 20134:35 pmRNSPrice Monitoring Extension
17th May 20137:00 amRNSInterim Management Statement
16th May 20131:20 pmRNSHolding(s) in Company
8th May 20136:09 pmRNSHolding(s) in Company
8th May 20135:47 pmRNSHolding(s) in Company
2nd May 20131:45 pmRNSHolding(s) in Company
1st May 20134:35 pmRNSPrice Monitoring Extension
30th Apr 20137:00 amRNSFinal Results
26th Apr 20134:50 pmRNSHolding(s) in Company
24th Apr 20133:47 pmRNSHolding(s) in Company
26th Mar 20134:40 pmRNSSecond Price Monitoring Extn
26th Mar 20134:35 pmRNSPrice Monitoring Extension
22nd Mar 201311:50 amRNSHolding(s) in Company
20th Mar 20131:15 pmRNSHolding(s) in Company
19th Mar 201311:34 amRNSForm 8.3 - Ark Therapeutics
19th Mar 20139:47 amRNSHolding(s) in Company
18th Mar 20131:54 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Mar 201312:01 pmRNSTermination of Offer Period and Rule 10.8 Waiver
7th Mar 20134:22 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 20133:04 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 201310:02 amRNSForm 8.3 - Ark Therapeutics Group Plc
1st Mar 201311:49 amRNSForm 8.3 - Ark Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.